Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Pharming Group (PHAR) Stock Price & Analysis

243 Followers

PHAR Stock Chart & Stats

$13.40$0.18(1.36%)
At close: 4:00 PM EST
$10$12.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$12.92 - $13.40
52-Week Range
$9.11 - $21.34
Previous Close
$13.22
Volume
N/A
Average Volume (3M)
14.60K
Market Cap
$916.95M
Enterprise Value
$670.87M
Total Cash (Recent Filing)
$189.56M
Total Debt (Recent Filing)
$114.51M
Price to Earnings (P/E)
37.4
Beta
0.37
Next Earnings
Mar 18, 2027 (Est.)
EPS Estimate
0.1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Pediatric Regulatory Expansion

The U.K. pediatric approval expands Joenja’s authorized population and strengthens Pharming’s position in targeted rare-disease treatment. Broader eligibility can support additional patient identification, international commercialization, and recurring therapy revenue over the coming quarters.

Joenja Growth And Market Expansion

Rapid Joenja growth, rising patients on paid therapy, and expansion into Germany and Japan indicate increasing commercial adoption beyond the initial U.S. market. A growing treated population and international reach can create a durable second product franchise.

Liquidity And Cash Generation

Positive operating cash flow and substantial liquidity give Pharming capacity to fund pipeline development, pediatric launches, and prelaunch costs without near-term external financing. This supports strategic flexibility while the company builds its rare-disease portfolio.

Bears Say

Unresolved CEO Transition

An unresolved leadership transition can create execution and strategic continuity risk while Pharming is commercializing Joenja and advancing multiple clinical programs. Interim leadership may also delay major decisions or reduce clarity around long-term priorities.

RUCONEST Competitive Pressure

Expected U.S. revenue contraction and the prospect of another oral competitor indicate ongoing pressure on Pharming’s largest established product. Sustaining patient retention, prescription volume, and growth may require continued commercial effort as treatment alternatives expand.

Uneven Profitability And Cash Flow

The return to positive cash generation is encouraging, but prior negative cash flow and modest operating profitability show that earnings conversion has not been consistent across the cycle. This may constrain reinvestment flexibility if product growth or margins weaken.

Pharming Group News

PHAR FAQ

What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was $9.11 and its highest was $21.34 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is $916.95M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s next earnings report is estimated for Mar 18, 2027 (not yet confirmed), which is in 126 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Oct 27, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.09.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is 0.10.
How many shares outstanding does Pharming Group have?
Pharming Group has 70,778,120 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of $0.3 in its last earnings report, beating expectations of $0.21. Following the earnings report the stock price went down -0.252%.
Which hedge fund is a major shareholder of Pharming Group?
Hedge funds hold Pharming Group shares: the largest hedge-fund position in Pharming Group is 71,856,998 shares, and hedge funds decreased their holdings by 326.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology